Background {#s001}
==========

F[emale sexual dysfunction]{.smallcaps} (FSD) is a common condition, estimated to occur in ∼40% of women in the United States. However, a recent study of 3000 women found that only 1/3 of women with a distressing sexual problem seek help from a healthcare professional, and only 6% schedule a visit to specifically discuss their sexual concerns.^[@B1],[@B2]^ While sexual dysfunction is estimated to be of higher prevalence for women (∼40%) versus men (∼30%), there is currently only one FDA-approved medication for FSD, specifically for hypoactive sexual desire disorder.^[@B3],[@B4]^

Key factors for women\'s sexual dysfunction include physical change(s) in a woman\'s vaginal tissue integrity secondary to childbirth, aging, or other connective tissue influencers, which can be associated with greatly reduced physical sensation during intercourse and diminished sexual satisfaction.^[@B3]^ These physical changes to the vagina (sometimes referred to as "vaginal laxity" in the medical and scientific literature) can cause the vaginal opening to feel looser to the woman and/or her sexual partner during penetration.

The exact prevalence of vaginal laxity after childbirth and other etiologies has yet to be determined. However, the association of patient-reported vaginal introital laxity with associated distressing sexual function is reported in the literature by both healthcare providers and by patients themselves. Vaginal laxity is a frequently unreported medical condition^[@B6]^ that negatively impacts female sexual function, self-image, and may directly impact quality of life (QOL).^[@B9]^ A recent study showed 50% of parous women were concerned about vaginal laxity, yet ∼80% of them failed to discuss their concern with their obstetrician/gynecologist.^[@B5]^ A study of urogynecologists showed vaginal laxity negatively impacts their patients\' QOL, sexual function, sexual satisfaction, and relationship happiness; they further identified the vaginal introitus as the most frequently cited location of laxity, with symptoms arising from changes in the integrity of both muscle and vaginal tissue.^[@B6]^

Vaginal laxity reports are based on patient-reported outcome instruments, including the patient\'s perception of her own vaginal looseness and/or symptoms of the vaginal looseness related to sexual function. This is due to the fact that presently, no reliable objective instrument exists to accurately measure, diagnose, or classify vaginal laxity or to furthermore correlate vaginal size/anatomy with sexual function.^[@B13]^

A recent review of the literature found just five examples of nonsurgical treatments that were published in peer-reviewed literature or on [clinicaltrials.gov](clinicaltrials.gov).^[@B20]^ Of these, one was for muscle training, one was using the Erbium:YAG laser, and three were using a radiofrequency device with cryogen cooling. Radiofrequency (RF) energy has a long history of use in sensitive tissues, such as mucosal tissue in the vagina,^[@B21]^ cornea,^[@B24]^ and skin.^[@B27],[@B28]^ The device used in the VIVEVE I trial delivers dual-mode, monopolar, radiofrequency energy with cryogen cooling to protect the superficial mucosa, while enabling heat to reach deeper into the underlying tissue layers. This dual-mode therapy uses heating and cooling to activate fibroblasts to produce new collagen and stimulate remodeling of vaginal tissue without evidence of fibrosis or underlying scarring, thereby providing additional support to the connective tissue matrix of the introitus and associated genitopelvic structures.^[@B21],[@B27],[@B29]^

Preclinical studies of cryogen-cooled monopolar radiofrequency (CMRF) delivered to the vaginal introitus demonstrated nonfibrotic collagen deposition up to 6 months posttreatment.^[@B30],[@B31]^ Two single-arm, pilot studies in women with vaginal laxity showed CMRF therapy was safe and effective at 6 and 12 months postintervention.^[@B14],[@B15]^ Also, the completion of this VIVEVE I randomized clinical trial now provides the first comparative effectiveness data between a standard clinical treatment and a Sham treatment to support the safe and effective use of CMRF therapy for the treatment of vaginal laxity.

This subanalysis of the VIVEVE I trial aimed to evaluate the impact of CMRF therapy of the vaginal introitus on each of the Female Sexual Function Index (FSFI) domains of sexual function. The VIVEVE I trial is the first randomized, placebo-controlled trial with a Sham arm of energy-based therapy for the treatment of vaginal laxity for improved sexual function.^[@B38]^

Materials and Methods {#s002}
=====================

Study design and research subjects {#s003}
----------------------------------

The VIVEVE I study was a multicenter, prospective, randomized, single-blind Sham-controlled trial that was conducted between January 2015 and March 2016 at nine centers in Canada, Spain, Italy, and Japan. The VIVEVE I trial was registered at [clinicaltrials.gov](clinicaltrials.gov) (NCT02261974). The research sites\' principal investigators were obstetricians/gynecologists or urogynecologists based in private clinics or in associated divisions of larger academic or medical institutions. Written informed consent was obtained before screening. Local ethics committees or institutional review boards for each study center approved the overarching trial protocol, which adhered to the Declaration of Helsinki. The same assessments and procedures were carried out for all subjects, regardless of any site-specific required modifications (*i.e.*, one additional inclusion criterion and a reordering of efficacy assessments).

Women presenting at the participating study centers with self-reported vaginal laxity were invited to participate in study screening. Printed media, radio, and Facebook ads were also used for patient recruitment. The VIVEVE I trial included premenopausal females (≥18 years of age) with ≥1 term vaginal delivery and self-reported vaginal laxity during sexual intercourse (classified by a score of ≤3 on a Vaginal Laxity Questionnaire). Women were excluded from the trial if they had an abnormal genitopelvic exam, were currently pregnant or breastfeeding, had a history of genital fistula or a thin rectovaginal septum, or had clinically significant pelvic organ prolapse. For the purpose of evaluating the impact of CMRF therapy in subjects with preexisting sexual dysfunction, this subanalysis was restricted to female subjects with sexual dysfunction, as defined by an FSFI total score ≤26.5 at the screening visit.

Randomization and intervention {#s004}
------------------------------

Study subjects meeting the inclusion/exclusion criteria were randomized 2:1 to receive either Active or Sham treatment in an effort to maximize the amount of safety data that were gathered. The Active group was randomized to receive a CMRF energy dose of 90 J/cm^2^; the Sham group was randomized to receive a nontherapeutic energy dose of ≤1 J/cm^2^.

Regardless of the randomized treatment assignment, subjects received 1 outpatient treatment of up to 110 pulses. For both treatment arms, a standard coupling fluid was applied to the vaginal introitus and device handpiece to ensure effective CMRF transfer. [Figure 1](#f1){ref-type="fig"} shows the Viveve System with the handpiece and a treatment tip attached. [Figure 2](#f2){ref-type="fig"} provides a closer look at the handpiece and treatment tip. For both treatment arms, a single-use tip (Active or Sham) delivered CMRF therapy circumferentially to the vaginal mucosal surface, avoiding the urethral area, in ∼0.5 cm overlapping intervals for five complete passes. Each treatment took ∼30 minutes to complete. A treatment consisting of less than 80 pulses was considered a partial treatment; subjects who received a partial treatment were asked to continue in the study at least until the 1-month follow-up to ensure that no adverse effects were observed. No prescribed pretreatment or posttreatment medications were required.

![Investigational product: Viveve System.](fig-1){#f1}

![Investigational product component: handpiece with treatment tip.](fig-2){#f2}

All subjects received the same follow-up and care; hence, they were treated exactly the same throughout the study, regardless of their assigned randomization group. The only exception was that the treatment tip used for the Sham group was specially programmed to deliver ≤1 J/cm^2^. This allowed the subjects to remain blinded to the treatment they received during the procedure. Postprocedure, both Sham and Active subjects were requested to refrain from vaginal intercourse or the use of tampons for a period of 10 days.

Follow-up and study exit {#s005}
------------------------

The FSFI questionnaire was administered at the screening visit (baseline) and at months 1, 3, and 6 postintervention. Adverse events were also recorded at these study intervals. Study exit occurred after completion of the 6-month follow-up visit, unless the subject requested to leave the study early or was lost to follow-up. In the Active group, eight subjects did not complete the 6-month follow-up visit for a variety of reasons: two subjects received partial treatment and were not required to complete the 6-month visit; three subjects withdrew consent; two subjects were lost to follow-up, and one subject sustained an injury that prevented her from continuing in the trial. This subject sustained a herniated disk from a skiing accident that left her incapable of intercourse as she recovered, and she was thus unable to provide appropriate responses to the study questionnaires. One subject in the Sham group, having received a partial treatment, was followed up until the 1-month visit; all other subjects in this randomization group completed their 6-month treatments.

FSFI assessment {#s006}
---------------

The endpoint of focus for this publication, the FSFI, is a widely accepted, global assessment used in female sexual medicine trials, which has been validated in many languages and for a variety of patient populations.^[@B16],[@B39]^ The formally validated English, Spanish, French, and Italian versions of the FSFI were used in this study.

The FSFI includes 19 questions ([Supplementary Table S1](#SD1){ref-type="supplementary-material"}; Supplementary Data are available online at [www.liebertpub.com/jwh](www.liebertpub.com/jwh)), categorized into 6 domains, which evaluate a woman\'s recent state of sexual function (*i.e.*, within the past 4 weeks). The minimum and maximum scores for each domain range from 0 to 6 (except for the "Desire" and "Satisfaction" domains, where the minimum scores are 1.2 and 0.8, respectively). The "Desire" domain includes two questions to assess sexual desire or interest. The "Arousal" domain includes four questions to assess sexual arousal and excitement during sexual activity or intercourse. The "Lubrication" domain includes four questions to assess lubrication and "wetness" during sexual activity or intercourse. The "Orgasm" domain includes three questions to assess the ability to reach orgasm or climax during sexual activity or intercourse. The "Satisfaction" domain includes three questions to assess satisfaction with their sexual relationship with their partner and overall sex life. The "Pain" domain includes three questions to assess pain or discomfort during and following vaginal penetration.

The domain scores combine to create a total score (range 2--36). A total FSFI score ≤26.55 is recognized in the medical literature as indicating sexual dysfunction.^[@B40]^ In validation studies, the FSFI demonstrated excellent discriminant validity for all domains of sexual function, including the ability to accurately discriminate sexual function from sexual dysfunction.^[@B41]^

Scoring for each FSFI domain and the FSFI total score are presented in [Supplementary Table S2](#SD2){ref-type="supplementary-material"}.

Statistical analyses {#s007}
--------------------

The VIVEVE I trial was powered to detect statistically significant and clinically important differences between the Active and Sham treatment groups for the primary outcome of "no vaginal laxity." The sample size for the VIVEVE I primary analysis was derived using the combined results from two single-arm pilot studies in the United States and Japan.^[@B14],[@B15]^ It is well recognized that "placebo" or "Sham" effects can be substantial, especially for subjective endpoints such as assessments of health-related QOL, including the FSFI used to assess female sexual health in this trial. To obtain a causative treatment effect, the VIVEVE I trial employed the requisite two-arm design to distinguish a bona fide, causative treatment effect from either a placebo/Sham effect or chance alone. The secondary analyses (presented in this subanalysis) of the FSFI domains of sexual function included approximately two-thirds of the subjects included in the VIVEVE I trial.

The first efficacy assessment included in this subanalysis was the change from baseline (CFB) to 6 months postintervention for each of the six FSFI domains of sexual function. The CFB analyses were determined using observed raw mean scores for each FSFI domain (calculated as the 6-month value minus the baseline value). In addition, adjusted mean change (AMC) values were determined using analysis of covariance (ANCOVA) adjusted for the baseline FSFI domain value and treatment group.

The second efficacy assessment was to determine minimal clinically important differences (MCID) using receiver operating characteristics (ROC) and the cumulative distribution function. The MCID was estimated using anchor-based methodology, which relates the magnitude of change on each FSFI domain to an independent measure reflecting the extent of a subject\'s perceived treatment benefit (*i.e.*, the anchor). Anchoring methodology and ROC were used to establish the minimum change (*i.e.*, improvement) on each domain of sexual function that was clinically important (*i.e.*, the MCID) at 6 months. The percentage of subjects who achieved the MCID for each FSFI domain assessment was determined. MCID odds ratios and 95% confidence intervals were estimated using logistic regression adjusted for the baseline FSFI domain value and treatment group. The binary (yes/no) "anchoring" question used in the MCID analyses included a single question at each follow-up time point: "Overall, do you believe that you have experienced a meaningful benefit from the study treatment procedure?"

In addition, the FSFI total score mean values are included for Active- and Sham-treated subjects at baseline and 1, 3, and 6 months postintervention.

The analysis set, for this subanalysis, included randomized subjects with a baseline FSFI score ≤26.5 who received complete or partial treatment and who completed the baseline and 6-month FSFI efficacy assessment. *Post-hoc* power calculations were not conducted and no adjustments were made for multiplicity. Results from these secondary analyses should be interpreted as exploratory and hypothesis generating. All analyses were compared using a two-sided significance level of 0.05. The assumptions of normality of error distribution (*i.e.*, homoscedasticity) and linearity were assessed for the ANCOVA analyses. Statistical analyses were conducted using STATA version 14 (Stata Corp. College Station, TX).

Results {#s008}
=======

Participants {#s009}
------------

Between January 2015 and March 2016, 108 subjects \[Active treatment (*n* = 73) and Sham treatment (*n* = 35)\] met all study inclusion/exclusion criteria, completed the baseline and 6-month FSFI assessment, and had a baseline FSFI total score ≤26.5. [Table 1](#T1){ref-type="table"} shows baseline characteristics for subjects in each treatment group. Overall, the baseline characteristics were similar for subjects in the Active and Sham groups.

###### 

[Baseline Characteristics and Maternal History]{.smallcaps}

                                        *Active treatment*^[a](#tf1){ref-type="table-fn"}^   *Sham treatment*
  ------------------------------------- ---------------------------------------------------- ------------------
  No. of subjects in the analysis set   73                                                   35
  Demographic data, mean (SD)                                                                
   Age                                  40.1 (6.4)                                           40.1 (5.9)
  Age categories, *N* (%)                                                                    
   \<35 years                           14 (19.2)                                            7 (20.0)
   35--39 years                         19 (26.0)                                            7 (20.0)
   40--44 years                         23 (31.5)                                            12 (34.3)
   ≥45 years                            17 (23.3)                                            9 (25.7)
  Clinical data, mean (SD)                                                                   
   BMI                                  24.5 (5.0)                                           25.1 (6.3)
  BMI categories, *N* (%)                                                                    
   BMI \<20                             7 (9.6)                                              4 (11.4)
   BMI 20--24                           40 (54.8)                                            18 (51.4)
   BMI 25--29                           16 (21.9)                                            8 (22.9)
   BMI ≥30                              10 (13.7)                                            5 (14.3)
  Comorbidities, *N* (%)                                                                     
   Ear, nose, or throat condition       3 (4.1)                                              5 (14.3)
   Dermatologic condition               6 (8.2)                                              2 (5.7)
   Pulmonary condition                  1 (1.4)                                              3 (8.6)
   Hepatic/biliary condition            2 (2.7)                                              3 (8.6)
   Endocrine condition                  8 (11.0)                                             3 (8.6)
   Neurologic condition                 8 (11.0)                                             2 (5.7)
   Psychiatric condition                2 (2.7)                                              1 (2.9)
   Hematologic condition                5 (6.8)                                              5 (14.3)
   Allergies                            14 (19.2)                                            7 (20.0)
   Gynecologic condition                16 (21.9)                                            7 (20.0)
  Other health status data, *N* (%)                                                          
   Prior surgery                        50 (68.5)                                            24 (68.6)
   Major illness within 5 years         9 (12.3)                                             2 (5.7)
   Prior sexually transmitted disease   3 (4.1)                                              1 (2.9)
  Maternal history, mean (SD)                                                                
   No. of pregnancies                   2.8 (1.5)                                            2.5 (1.3)
   No. of full-term deliveries          2.2 (0.9)                                            2.0 (0.8)
   Time since last delivery (years)     7.9 (6.4)                                            8.3 (5.5)
   No. of vaginal deliveries            2.1 (1.0)                                            1.9 (0.9)

All baseline characteristics were not statistically different (α = 0.05) for the Active versus Sham treatment groups.

BMI, body mass index.

FSFI total score results {#s010}
------------------------

Mean FSFI total score values at baseline and months 1, 3, and 6 are described in [Figure 3](#f3){ref-type="fig"}. Baseline values were similar between Active and Sham groups. Subjects who received Active treatment showed greater overall FSFI improvement than Sham subjects. The mean FSFI total score for Active subjects improved from sexually "dysfunctional" to "functional" at 1, 3, and 6 months postintervention, whereas, the mean FSFI total score for Sham-treated subjects did not reach sexually "functional" at any follow-up time point.

![FSFI total score: mean values at baseline and at each follow-up time point. FSFI, Female Sexual Function Index. Note: The reference line at FSFI total score = 26.5 represents the threshold for classifying female sexual dysfunction (FSD).^[@B40]^](fig-3){#f3}

FSFI domain results summary {#s011}
---------------------------

The ANCOVA CFB analyses for each FSFI domain of sexual function at 6 months postintervention are presented in [Table 2](#T2){ref-type="table"}. Baseline values for each FSFI domain were similar for both treatment groups. Subjects in the Active group had greater improvement on all six domains of sexual function than subjects in the Sham group. The AMC from baseline to 6 months shows statistically significant improvements (at the 0.05 significance level) for subjects in the Active treatment group (vs. Sham) in the Arousal, Lubrication, and Orgasm domains of sexual function. There was a borderline significant improvement (*p* = 0.053) in the Desire domain. Among all FSFI domains of sexual function, the greatest differences between Active and Sham treatment were observed for the Arousal and Orgasm domains.

###### 

[Female Sexual Function Index Domains of Sexual Function: Mean Values and Adjusted Mean Change at Baseline and 6 Months Postintervention]{.smallcaps}

  *FSFI domains*   *Treatment group*   *Baseline*^[a](#tf3){ref-type="table-fn"}^*mean*   *6-Month mean*   *Adjusted*^[b](#tf4){ref-type="table-fn"}^*mean change*   p-*value*^[c](#tf5){ref-type="table-fn"}^
  ---------------- ------------------- -------------------------------------------------- ---------------- --------------------------------------------------------- -------------------------------------------
  Desire           Active              2.92                                               3.72             0.82                                                      0.053
                   Sham                2.90                                               3.33             0.42                                                       
  Arousal          Active              3.12                                               4.39             1.27                                                      0.004^[c](#tf5){ref-type="table-fn"}^
                   Sham                3.30                                               3.80             0.62                                                       
  Lubrication      Active              3.78                                               5.07             1.30                                                      0.040^[c](#tf5){ref-type="table-fn"}^
                   Sham                3.90                                               4.59             0.77                                                       
  Orgasm           Active              3.07                                               4.23             1.24                                                      0.007^[c](#tf5){ref-type="table-fn"}^
                   Sham                3.18                                               3.53             0.51                                                       
  Satisfaction     Active              3.65                                               4.60             1.04                                                      0.124
                   Sham                3.35                                               4.14             0.66                                                       
  Pain             Active              4.85                                               5.14             0.27                                                      0.083
                   Sham                4.79                                               4.72             −0.13                                                      

The baseline FSFI assessment was conducted before the intervention.

The adjusted mean change was estimated from individual ANCOVA models (for each domain), which included the baseline domain score and treatment group as independent variables.

*p*-value deemed statistically significant as ≤ 0.05.

ANCOVA, analysis of covariance; FSFI, Female Sexual Function Index.

The MCID analyses at 6 months posttreatment are presented in [Table 3](#T3){ref-type="table"}. These analyses evaluated the difference in the proportion of Active versus Sham subjects who experienced what they perceived to be a clinically meaningful treatment benefit relative to change on each FSFI domain assessment. For all FSFI domains of sexual function, subjects in the Active treatment group had a greater perception of achieving a clinically meaningful treatment benefit compared to subjects in the Sham group.

###### 

[Minimal Clinically Important Difference Analyses at the 6-Month Time Point for Each Female Sexual Function Index Domain of Sexual Function]{.smallcaps}

  *FSFI domains*   *Treatment*   *MCID value*^[a](#tf8){ref-type="table-fn"}^   N    *≥MCID* N′ *(%)*   *MCID odds ratio*^[b](#tf9){ref-type="table-fn"}^   *95% CI*   p-*value*^[c](#tf10){ref-type="table-fn"}^   
  ---------------- ------------- ---------------------------------------------- ---- ------------------ --------------------------------------------------- ---------- -------------------------------------------- ----------------------------------------
  Desire           Active        0.7                                            73   37.9965            52.1                                                3.01       1.11--8.17                                   0.031^[c](#tf10){ref-type="table-fn"}^
                   Sham                                                         35   11.998             34.3                                                                                                         
  Arousal          Active        1.0                                            73   44.9972            61.6                                                2.73       1.06--7.04                                   0.037^[c](#tf10){ref-type="table-fn"}^
                   Sham                                                         35   14                 40.0                                                                                                         
  Lubrication      Active        1.0                                            73   41.9969            57.5                                                1.58       0.57--4.35                                   0.376
                   Sham                                                         35   15.9985            45.7                                                                                                         
  Orgasm           Active        0.5                                            73   48.9976            67.1                                                2.58       1.08--6.18                                   0.034^[c](#tf10){ref-type="table-fn"}^
                   Sham                                                         35   16.9995            48.6                                                                                                         
  Satisfaction     Active        0.9                                            73   35.0035            48.0                                                1.53       0.57--4.13                                   0.400
                   Sham                                                         35   14.413             41.2                                                                                                         
  Pain             Active        0.1                                            73   26.0026            35.6                                                2.17       0.52--8.98                                   0.286
                   Sham                                                         35   11.0005            31.4                                                                                                         

*N*′ = number of subjects who achieved at least the MCID value.

The MCID value was determined for each FSFI domain of sexual function at the 6-month time point. This value represents the smallest change (6-month value and baseline value) that a subject would identify as clinically important.

MCID odds ratios were estimated using multivariable logistic regression with treatment group and baseline score as independent variables.

*p*-value deemed statistically significant as ≤ 0.05.

CI, confidence interval; FSFI, Female Sexual Function Index; MCID, minimal clinically important difference.

The MCID for the FSFI arousal assessment was an improvement of at least 1.0 point from the baseline arousal assessment to the 6-month arousal assessment. Forty-five (45/73; 61.6%) and 14 (14/35; 40.0%) subjects in the Active and Sham groups, respectively, achieved an improvement of ≥1.0 point on the sexual arousal assessment (baseline vs. 6 month). The MCID odds ratio \[OR\] (95% CI) shows subjects in the Active treatment group were more than 2.7 times as likely to achieve a clinically meaningful and statistically significant treatment benefit regarding their perception of sexual arousal compared to Sham-treated subjects \[OR = 2.73 (1.06--7.04)\]. In addition to the FSFI Arousal domain, subjects in the Active treatment group achieved a clinically important and statistically significant improvement regarding their perception of orgasm \[OR = 2.58 (1.08--6.18)\] and desire \[OR = 3.01 (1.11--8.17)\] compared to Sham subjects.

Discussion {#s012}
==========

Building on two single-arm pilot studies,^[@B14],[@B15]^ the VIVEVE I trial was the first, multicenter, randomized, Sham-controlled study to evaluate the efficacy of a nonsurgical modality for the treatment of vaginal introital laxity. For the FSFI domain subanalyses, Active CMRF therapy demonstrated superiority over Sham using this validated assessment of sexual function among subjects with baseline FSD as defined by a baseline FSFI total score ≤26.5. The CMRF procedure was well tolerated and showed an excellent 6-month safety profile (data not presented). No topical anesthetic was required and there were no serious adverse events reported in the Active group. In addition, the percentage of subjects reporting a related adverse event that occurred either during or after treatment was essentially the same in both the Active and Sham groups. In the evaluation of adverse events by the site investigator and medical monitor, adverse events were counted as "Related" if the relationship was recorded as "Possibly Related," "Related," or "Unknown/Undetermined," or if the relationship was missing. Examples of "Related" adverse events common to both groups included individual reports of vaginal discharge, mild uterine cramping, and a sensation of warmth during or following the procedure. There is a more detailed description of adverse events in the primary study publication.^[@B38]^

The efficacy results of this subanalysis show statistically significant and clinically important improvements in Arousal, Lubrication, and Orgasm domains associated with Active treatment in the target patient population. While the improvement for the Desire domain showed a clinically important improvement, as assessed by MCID, this did not achieve statistical significance. Improvements were also associated with Active treatment for the Satisfaction and Pain domains; however, these did not achieve statistical significance. The results for the Satisfaction domain are not surprising since this domain incorporates multifactorial elements of overall sexual satisfaction (*e.g.*, emotional closeness with partner). In addition, as women were not preselected for pain with intercourse in this study (indeed, they were excluded with untreated dyspareunia), large changes in this domain would also not be expected.

The positive efficacy results from this trial support the proposed mechanism of action, as well as the safe delivery of minimally invasive CMRF therapy to vaginal tissue in women who have self-reported vaginal laxity and FSD as evaluated by baseline FSFI total scores. The statistically significant and clinically important results seen with CMRF may be explained by an effect on the genitopelvic-clitoral complex by enhancement of the structural integrity by enriched fibroblastic deposited connective tissue. This underlying architectural modification may improve neural, hormonal, and vascular flow to the underlying structural components, including the circumferential crural arms of the clitoral arousal complex, hence enhancing both genital arousal and potentially improving orgasmic intensity, while decreasing orgasmic latency, lending to the patient-reported improvements in sexual function observed in the VIVEVE I study in various domains of the FSFI.

While CMRF therapy was associated with statistically significant and clinically important improvements of sexual function (in favor of Active treatment), a short-lived Sham effect at months 1 and 3 was observed. For Sham-treated subjects, improvements diminished by 6 months and the mean FSFI total score for Sham-treated subjects never achieved sexually "functional" status (FSFI total score \>26.5), even at the earlier time points. This is not surprising, as a significant placebo response has been observed in several FSD trials.^[@B42]^ It also is an established principle in the field of sexual health that an individual\'s mental perception can have a profound effect on their overall sexual function and satisfaction.^[@B45],[@B46]^ If one has a negative impression of one\'s capacity for sexual function, it can directly impact physiological, biological, and chemical reactivity, and subsequent sexual responsiveness. The Sham effect underscores the importance of conducting rigorous research investigations with adequate follow-up time and a comparator group (*e.g.*, Sham or placebo) to ensure the treatment effect is attributable to the intervention and is beyond the effects gained from an office visit or counseling with a healthcare professional alone.

This subanalysis had several limitations worth noting. No control for multiplicity was implemented for the *post hoc* analyses of the VIVEVE I trial; therefore, results should be interpreted as exploratory or hypothesis generating. In addition, the generalizability of the study findings is restricted to women with self-reported vaginal laxity and FSD as defined by a baseline FSFI total score ≤26.5. Women who were sexually functional (*i.e.*, baseline FSFI total score \>26.5) were not analyzed as part of this subanalysis. That said, a substantial proportion of parous women fall into this category. In the VIVEVE I trial, 66% of included subjects presented with sexual dysfunction at the screening visit. Finally, early system characteristics made double blinding of treatment assignment difficult to achieve. While all subjects were unaware of their treatment assignment for the entire study duration, the site investigator was aware of treatment assignment. Despite this limitation, similar baseline characteristics and study drop-out rates for subjects in the Active and Sham groups empirically suggest that bias was not introduced by investigator channeling or differential study conduct by treatment assignment throughout the entire duration of trial follow-up. The robust "Sham" effect in the first 3 months further indicates that study validity was not compromised by single blinding. To mitigate the potential for investigator channeling bias, subjects assigned to the Sham group were permitted to receive the Active CMRF therapy upon study completion.

Conclusion {#s013}
==========

This subanalysis of the VIVEVE I trial showed that a single, nonablative CMRF treatment significantly improves overall sexual function (FSFI total score) in women with FSD and self-reported vaginal laxity. Of the six domains of the FSFI, the improvement achieved using CMRF therapy is primarily being driven by the statistically significant and/or clinically important improvements in sexual desire, arousal, lubrication, and orgasm in women with vaginal laxity and baseline sexual dysfunction. The findings of sexual function improvement provide evidence for the clinical utility, and direction for further evaluation, of this novel, single treatment, 30-minute, nonsurgical outpatient modality for a highly prevalent and undertreated condition. Furthermore, these results underscore the importance of conducting rigorous research using a randomized Sham or placebo comparator arm with adequate follow-up time to permit the estimation of a valid treatment effect.
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